Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy

Not Applicable

• Conditions: advanced advanced for gastric cancer patients with prior chemotherapy

• Registration Number: JPRN-UMIN000013105
• Lead Sponsor: Toho University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-02-10
• Study Completion: 2016-04-05
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

1)patients previously treated with Nab-paclitaxel,paclitaxel derivative drugs 2)peripheral neuropathy 3)History of serious drug hypersensitivity 4)active synchronous malignancy with longer than 5 year interval period 5)Uncontrolled unstable angina, congestive heart failure, myocardial infarction or ventricular arrhythmia 6)Any other serious illness or medical conditions including interstitial pneumonia or pulmonary fibrosis, renal failure, liver failure,cerebrovascular disordar or Uncontrolled diabates 7)Active infection or fever suspicious of infection. 8)The case that uses a steroid regularly 9)Much amount of pleural effusion, ascites or cardiac effusion 10)Case having extensive bone metastasis 11)with brain metastasis 12)History of mental disorder, central nerve disorder 13)Pregnant women, nursing mothers 14)Patients who were considered by the primary care physician to be inappropriate for this trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival

Secondary Outcome Measures

Name	Time	Method
Response Rate Disease Contorol Rate Overall Survival Incidence and grade of Adverse Event,